181 related articles for article (PubMed ID: 31871314)
21. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
23. Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry.
Kallakury BV; Hartmann DP; Cossman J; Gootenberg JE; Bagg A
Am J Clin Pathol; 1999 Jun; 111(6):759-66. PubMed ID: 10361511
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission.
Chu SC; Wang TF; Su YC; Kao RH; Wu YF; Li DK; Li SC; Li CC; Wells DA; Loken MR
Int J Hematol; 2014 Mar; 99(3):296-304. PubMed ID: 24481944
[TBL] [Abstract][Full Text] [Related]
25. [THE COMPARISON OF RESULTS OF DETECTION OF MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD AND MARROW IN CHILDREN OF THE FIRST YEAR OF LIFE WITH ACUTE LYMPHOBLASTIC LEUCOSIS].
Tsaur GA; Riger TO; Popov AM; Nasedkina TV; Kustanovich AM; Solodovnikov AG; Streneva OV; Shorikov EV; Tsvirenko SV; Saveliev LI; Fechina LG
Klin Lab Diagn; 2015 Apr; 60(4):14-22. PubMed ID: 26189286
[TBL] [Abstract][Full Text] [Related]
26. Clinical value to quantitate hematogones in Chinese childhood acute lymphoblastic leukemia by flow cytometry analysis.
Wang Y; Peng L; Dai Q; Ye L; Chen L; Chen Q; Lai C; Jiang Y; Zhang G
Int J Lab Hematol; 2016 Jun; 38(3):246-55. PubMed ID: 26991766
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
28. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
29. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
31. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
32. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
33. Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis.
Don MD; Lim W; Lo A; Cox B; Huang Q; Kitahara S; Lopategui J; Alkan S
Am J Clin Pathol; 2020 May; 153(6):790-798. PubMed ID: 32068791
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of CD34(+)CD38(+) and CD34(+)CD38(low/-) subgroups in bone marrow of patients with B lymphoblastic leukemia].
Hao L; Liu YR; Wang YZ; Chang Y; Qin YZ; Li JL; Li LD; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):801-5. PubMed ID: 22931632
[TBL] [Abstract][Full Text] [Related]
35. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
[TBL] [Abstract][Full Text] [Related]
38. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
39. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
40. Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes.
Park HS; Kim DY; Choi EJ; Lee JH; Lee JH; Jeon M; Kang YA; Lee YS; Seol M; Cho YU; Jang S; Chi HS; Lee KH; Park CJ
Acta Haematol; 2018; 139(4):220-227. PubMed ID: 29860259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
